KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Revenue (2016 - 2025)

Historic Revenue for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $70.4 million.

  • Novavax's Revenue fell 1664.5% to $70.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1301.61%. This contributed to the annual value of $682.2 million for FY2024, which is 3065.38% down from last year.
  • Per Novavax's latest filing, its Revenue stood at $70.4 million for Q3 2025, which was down 1664.5% from $175.0 million recorded in Q2 2025.
  • Novavax's Revenue's 5-year high stood at $734.6 million during Q3 2022, with a 5-year trough of $70.4 million in Q3 2025.
  • In the last 5 years, Novavax's Revenue had a median value of $222.2 million in 2021 and averaged $300.3 million.
  • As far as peak fluctuations go, Novavax's Revenue surged by 1314338.17% in 2021, and later tumbled by 8850.08% in 2023.
  • Novavax's Revenue (Quarter) stood at $222.2 million in 2021, then surged by 60.85% to $357.4 million in 2022, then fell by 18.48% to $291.3 million in 2023, then tumbled by 69.69% to $88.3 million in 2024, then decreased by 20.23% to $70.4 million in 2025.
  • Its Revenue was $70.4 million in Q3 2025, compared to $175.0 million in Q2 2025 and $666.7 million in Q1 2025.